Paul Lizzul Biography and Net Worth

Chief Medical Officer of AnaptysBio

Paul leads the company’s development organization, including clinical medicine, clinical operations, regulatory affairs, pharmacology and toxicology functions. Prior to Anaptys, he has served as global development lead for Inflammation at Amgen, chief medical officer of Sienna Biopharmaceuticals and senior medical director at Kythera Biopharmaceuticals. Paul served as assistant professor of Dermatology and conducted clinical research at Tufts Medical Center. He is a board-certified dermatologist, a faculty member of the American Academy of Dermatology and has served on the United States Food and Drug Administration (FDA) Dermatology and Ophthalmic Drugs Advisory Committee. Paul received his M.D., Ph.D. in molecular genetics and MPH in epidemiology from the Robert Wood Johnson Medical School at Rutgers. He has also earned an MBA in entrepreneurship from the Rutgers Business School.

What is Paul F. Lizzul's net worth?: The estimated net worth of Paul F. Lizzul is at least $2.76 million as of January 8th, 2026. Dr. Lizzul owns 42,088 shares of AnaptysBio stock worth more than $2,755,080 as of March 26th. This net worth approximation does not reflect any other investments that Dr. Lizzul may own. Learn More about Paul F. Lizzul's net worth.
How do I contact Paul F. Lizzul?: The corporate mailing address for Dr. Lizzul and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at [email protected]. Learn More on Paul F. Lizzul's contact information.
Has Paul F. Lizzul been buying or selling shares of AnaptysBio?: During the last quarter, Paul F. Lizzul has sold $446,526.29 in AnaptysBio stock. Most recently, Paul F. Lizzul sold 3,650 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a transaction totalling $163,191.50. Following the completion of the sale, the insider now directly owns 42,088 shares of the company's stock, valued at $1,881,754.48. Learn More on Paul F. Lizzul's trading history.
Who are AnaptysBio's active insiders?: AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Magda Marquet (Director), Dennis Mulroy (CFO), Hollings Renton (Director), Hamza Suria (CEO), and J. Ware (Director). Learn More on AnaptysBio's active insiders.
Are insiders buying or selling shares of AnaptysBio?: In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 177,205 shares worth more than $7,748,140.88. The most recent insider tranaction occured on February, 11th when insider Eric J Loumeau sold 10,000 shares worth more than $540,000.00. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.
Information on this page was last updated on 2/11/2026.

Paul F. Lizzul Insider Trading History at AnaptysBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/8/2026	Sell	3,650	$44.71	$163,191.50	42,088
1/7/2026	Sell	2,235	$45.11	$100,820.85	37,213
1/5/2026	Sell	4,219	$43.26	$182,513.94	33,303
12/22/2025	Sell	1,500	$50.00	$75,000.00	26,967
9/23/2024	Sell	1,500	$38.67	$58,005.00	15,398
7/18/2024	Sell	1,500	$35.00	$52,500.00	11,618
1/8/2024	Sell	2,554	$21.81	$55,702.74	10,118
9/14/2023	Sell	2,105	$19.48	$41,005.40	6,527

Paul F. Lizzul Buying and Selling Activity at AnaptysBio

AnaptysBio Company Overview

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Today's Range

Now: $64.99

$63.24

$67.00

50 Day Range

MA: $54.69

$45.68

$67.29

2 Week Range

Now: $64.99

$15.40

$68.39

Volume

252,621 shs

Average Volume

519,302 shs

Market Capitalization

$1.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32